Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 224.68% from the company’s current price.

Kiora Pharmaceuticals Trading Up 2.0 %

KPRX stock opened at $3.08 on Friday. Kiora Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $6.30. The stock has a market cap of $9.24 million, a P/E ratio of 2.96 and a beta of -0.46. The stock’s fifty day simple moving average is $3.46 and its two-hundred day simple moving average is $3.48.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Tuesday, March 25th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.40). The firm had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.75 million. As a group, analysts forecast that Kiora Pharmaceuticals will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC increased its stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent quarter. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.